eGenesis fetches $125m Series C
eGenesis, a gene-editing and genome-engineering company, has closed $125 million in Series C financing.
eGenesis, a gene-editing and genome-engineering company, has closed $125 million in Series C financing.
Copyright PEI Media
Not for publication, email or dissemination
